Funding announcement
Prota/MCRI completes enrolment of Phase 2b multicentre clinical trial of probiotic oral immunotherapy for the treatment of peanut allergy (PPOIT-003)
Prota Therapeutics finished enrolling 200 children in its Phase 2b peanut allergy immunotherapy trial, with results expected in early 2020; the MCRI-licensed treatment has been backed by OneVentures since inception.